Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Total revenue	$ 164.0	$ 216.6	$ 545.4	$ 635.7
Costs and expenses:
Research and development expense	19.7	21.5	59.8	65.0
Change in the fair value of contingent consideration	(3.4)		(2.8)	1.4
Selling, general, and administrative expense	132.9	140.6	402.7	405.7
Goodwill and intangible asset impairment charges	98.4		99.7
Total costs and expenses	297.7	210.7	708.8	622.5
Operating income (loss)	(133.7)	5.9	(163.4)	13.2
Other income (expense):
Interest income	0.8	0.7	2.5	2.3
Interest expense	(2.3)	(3.2)	(7.7)	(8.8)
Other	4.1	(0.1)	3.8	1.0
Total other income (expense):	2.6	(2.6)	(1.4)	(5.5)
Income (loss) before income tax	(131.1)	3.3	(164.8)	7.7
Income tax provision (benefit)	(15.9)	(3.6)	(20.7)	(1.0)
Net income (loss)	(115.2)	6.9	(144.1)	8.7
Net loss attributable to non-controlling interest				(0.1)
Net income (loss) attributable to Myriad Genetics, Inc. stockholders	$ (115.2)	$ 6.9	$ (144.1)	$ 8.8
Earnings (loss) per share:
Basic	$ (1.55)	$ 0.09	$ (1.94)	$ 0.12
Diluted	$ (1.55)	$ 0.09	$ (1.94)	$ 0.12
Weighted average shares outstanding:
Basic	74.5	73.3	74.2	73.5
Diluted	74.5	74.9	74.2	76.4
Molecular Diagnostic Testing [Member]
Total revenue	$ 150.5	$ 200.5	$ 503.6	$ 592.5
Costs and expenses:
Total costs and expenses	43.1	40.3	125.3	126.6
Pharmaceutical and Clinical Services [Member]
Total revenue	13.5	16.1	41.8	43.2
Costs and expenses:
Total costs and expenses	$ 7.0	$ 8.3	$ 24.1	$ 23.8